drugset
Drugs / mRNA-1273.529
last change Nov 2023 re-read 9 days ago

mRNA-1273.529

Messenger RNA (mRNA)

Developed for
COVID-19
Investigated by
ModernaTX, Inc. · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 3

today NCT05289037 · Ph 2 NCT05249829 · Ph 2/3 NCT04927065 · Ph 2/3
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT05289037 Mar 2022 → Nov 2023 COVID-19 National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2/32 trials · 2 met primary
Phase 2/3 NCT05249829 Feb 2022 → Jun 2023 COVID-19 ModernaTX, Inc. Completed Met primary
Phase 2/3 NCT04927065 May 2021 → Nov 2023 COVID-19 ModernaTX, Inc. Completed Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as mRNA-1273.529 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04927065 ↗
2

NCT05249829 ↗

NCT05289037 ↗
Modality Messenger RNA (mRNA) “containing an mRNA that encodes for the prefusion stabilized S protein” NCT05289037 ↗
Route Intramuscular “Participants will receive 1 intramuscular first booster dose of 50 μg of mRNA-1273.529 on Day 1.” NCT04927065 ↗